Evaxion A/S to Announce Q3 2025 Financial Results and Business Update

Evaxion A/S, a clinical-stage TechBio company specializing in AI-Immunology™ powered vaccines, announced that it will provide a business update and report its third quarter 2025 financial results on November 6, 2025. The company will host a conference call and webcast at 14:30 CET/08:30 EST on the same day, where the Executive Management will present the update and results, and take questions from participants. The event is open to the public, and registration is required for the conference call. The webcast recording will be available on the company's website shortly after the event. Evaxion is focused on developing novel immunotherapies for cancer, bacterial diseases, and viral infections using its AI-Immunology™ platform.